Clinical Trials | November 14, 2025
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
FIBROSARC did not meet its primary PFS endpoint in the final analysi
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Subscribe To Our Newsletter & Stay Updated
